AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alnylam Pharmaceuticals Slumps to 467th in Trading Volume Despite FDA Approval for AMVUTTRA
Generated by AI AgentAinvest Volume Radar
Wednesday, Jun 25, 2025 8:00 pm ET1min read
On June 25, 2025,
Inc. (ALNY) experienced a significant decline, with its trading volume reaching $204 million, a 36.59% decrease from the previous day. This placed at the 467th position in terms of trading volume for the day. The stock price of ALNY also decreased by 0.94%.Alnylam Pharmaceuticals Inc. recently received FDA approval for AMVUTTRA (vutrisiran), marking a significant milestone as the first RNAi therapeutic to reduce cardiovascular death and hospitalizations. This approval is expected to have a positive impact on the company's market position and financial performance.
Additionally, the European Commission (EC) has granted approval for Alnylam's Amvuttra to treat the rare heart disease ATTR-CM. This approval further solidifies Alnylam's leadership in the development of innovative therapies for rare diseases, potentially driving future growth and investor confidence.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Kraft Heinz Slides 1.02% as Stock Ranks 486th in Daily Trading Volume Amid Institutional Splits Earnings Woes and Dividend Strain Weigh on Investor Confidence
Dec.05 2025
AVAV's 3.15% Slide Amid 21% Volume Drop, 475th Rank Signal Earnings Optimism Fizzles
Dec.05 2025
Align Technology Extends Three-Day Rally with 0.24 Gain Ranks 452nd in $250M Turnover as Dental Sector Outperforms Peers
Dec.05 2025
PPG's 0.36% Rise Outpaces 448th-Ranked Volume as Analysts Boost Aerospace Growth Outlook
Dec.05 2025
Akamai's FedRAMP Certification Drives 31.33% Volume Surge to 445th Rank, but Stock Dips 3.59% on Investor Caution
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet